These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21327673)

  • 1. Efficacy of propiverine ER with or without α-blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study.
    Oelke M; Murgas S; Baumann I; Schnabel F; Michel MC
    World J Urol; 2011 Apr; 29(2):217-23. PubMed ID: 21327673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
    Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
    Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: A randomized, prospective, comparative trial using a urodynamic study.
    Matsukawa Y; Takai S; Funahashi Y; Kato M; Yamamoto T; Gotoh M
    Neurourol Urodyn; 2017 Mar; 36(3):748-754. PubMed ID: 27060991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
    Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A;
    Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of alfuzosin 10 mg with or without propiverine 10 mg, 20 mg in men with lower urinary tract symptom and an overactive bladder: randomised, single-blind, prospective study.
    Cho HJ; Shin SC; Seo DY; Cho JM; Kang JY; Yoo TK; Yu JH; Sung LH; Moon HS
    Int J Clin Pract; 2014 Apr; 68(4):471-7. PubMed ID: 24471868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
    Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms.
    McKeage K
    Clin Drug Investig; 2013 Jan; 33(1):71-91. PubMed ID: 23288694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia.
    Höfner K; Burkart M; Jacob G; Jonas U
    World J Urol; 2010 Jun; 28(3):353-7. PubMed ID: 19997921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial.
    Gotoh M; Yokoyama O; Nishizawa O;
    Int J Urol; 2011 May; 18(5):365-73. PubMed ID: 21332825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study.
    Lee KS; Choo MS; Kim DY; Kim JC; Kim HJ; Min KS; Lee JB; Jeong HJ; Lee T; Park WH
    J Urol; 2005 Oct; 174(4 Pt 1):1334-8. PubMed ID: 16145414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of propiverine and terazosine combination for one year in male patients with luts and detrusor overactivity.
    Sener NC; Ozturk U; Goktug HN; Gucuk A; Nalbant I; Yesil S; Abdurrahim MI
    Int Braz J Urol; 2013; 39(4):513-8. PubMed ID: 24054398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised, prospective double-blind, propiverine-controlled trial of imidafenacin in patients with overactive bladder.
    Park C; Park J; Choo MS; Kim JC; Lee JG; Lee JZ; Lee KS; Kim DY; Lee SJ; Seo JT
    Int J Clin Pract; 2014 Feb; 68(2):188-96. PubMed ID: 24373019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a randomized, double-blind, active-controlled clinical trial with propiverine extended release 30 mg in patients with overactive bladder.
    Leng J; Liao L; Wan B; Du C; Li W; Xie K; Shen Z; Xu Z; Wu S; Fang Z; Ma L; Han S; Feustel C; Yang Y; Madersbacher H
    BJU Int; 2017 Jan; 119(1):148-157. PubMed ID: 27087507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder.
    Jünemann KP; Hessdörfer E; Unamba-Oparah I; Berse M; Brünjes R; Madersbacher H; Gramatté T
    Urol Int; 2006; 77(4):334-9. PubMed ID: 17135784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
    Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
    BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
    Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Patterns and Patient Reported Outcomes in Benign Prostatic Hyperplasia Patients with Overactive Bladder Symptoms.
    Park YH; Kim TH; Lee SW; Chung BH; Cho JS; Lee JY
    Low Urin Tract Symptoms; 2017 May; 9(2):75-81. PubMed ID: 28394492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.